anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: The purpose of this review is to evaluate current literature on the treatment of factor Xa inhibitor-associated bleeds with 4-factor prothrombin complex concentrate (4F-PCC), with a focus on the effect of low versus high dosing of 4F-PCC on hemostatic efficacy and safety outcomes.
SUMMARY: A search of PubMed and EBSCOhost was performed to identify studies evaluating patients with a factor Xa inhibitor-bleed treated with 4F-PCC at either low or high doses. Studies of patients receiving alternative reversal agents such as fresh frozen plasma and andexanet alfa or where no comparator group was evaluated were excluded from the analysis. To assess the effect of these 4F-PCC dosing strategies, the primary outcome of interest was hemostatic efficacy. Four studies meeting inclusion criteria were included in this review. In each of the included studies, similar rates of hemostatic efficacy, hospital mortality, and venous thromboembolism were observed in the low- and high-dose cohorts.
CONCLUSION: These results suggest low- and high-dose 4F-PCC may confer similar clinical effectiveness and safety; however, these findings should be evaluated and confirmed with future prospective studies.
Before anesthesia induction, patients in the experimental group received 5-6L/min of oxygen for about 1min through the endoscopic bite connecting oxygen supply device, and patients in the control group inhaled 5-6L/min of oxygen for about 1min through the nasal catheter.Both groups were anesthetised with propofol 3mg/Kg and sufentanil 7ug.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. After the subjects achieved sufficient sedation (about BIS40), The ordinary endoscopic bite group began to perform endoscopic operation after sufficient sedation was achieved,In both groups, 5mg/Kg/h propofol was continuously pumped to maintain anesthesia until completion of the examination.
The second part of the study comprises of 2 arms. This is the first arm Days 1 through 14: An oral dose of pacritinib 200 mg (2 × 100 mg capsules) BID (approximately 12 hours apart) Days 8 through 14: An oral dose of bosentan 125 mg BID (approximately 12 hours apart) All the doses will be administered with approximately 240 mL of water.
The invention provides an application of an extract from leaves of Nauclea officinalis in preparing a drug for resisting Candida krusei. A preparation method of the extract from leaves of Nauclea officinalis comprises: accurately weighing a proper amount of leaves of Nauclea officinalis, refluxing and extracting with ethanol, concentrating the extracting solution, and evaporating to dryness to obtain the extract from leaves of Nauclea officinalis. The minimum inhibitory concentration (MIC) of the extract from the leaves of Nauclea officinalis is 47.2 μg/mL. The drug for resisting Candida krusei is oral dosage form or external dosage form. The oral dosage form is selected from decoction, granule, capsule, tablet, oral liquid, pill, tincture and syrup. The external dosage form is selected from gel, spray, ointment, patch, cataplasm, lotion, cream and suppository.
The CME children will be eligible for the study if they (1) had a diagnosis of CMA by OFC, except children with known anaphylaxis (2) those on a CME diet or a specialized infant formula for at least three months (3) had reintroduced cow's milk for at least three months ago. Children who excluded other foods in addition to cows' milk in the first four years of life for ≥ three months and who currently introduced these foods for at least ≥ three months will be also enrolled in the CME group.
Wheat is one of the most common causes in food-induced anaphylaxis and food dependent, exercised induced anaphylaxis. Gold standard for diagnose food allergy is double blind placebo control food challenge, but it is a high risk procedure. The accuracy of skin prick test and specific IgE assay showed unsatisfactory results. It might be explained by these tests may not detect all of the major allergens in wheat allergic patients. Previous studies showed that the major allergens of wheat dependent, exercised induced anaphylaxis are omega5 gliadin, followed by high molecular weight glutenin. For IgE-mediated wheat allergy, the major allergens varied among studies, including omega5 gliadin, glutenin, alpha/beta/gamma gliadin, and the water-soluble part of wheat allergens. There is no study to direct compare the major allergen between patients who have low wheat specific IgE and very high wheat specific IgE. Also, there is no data about the major allergens of wheat anaphylaxis in Thai population.
NEW MATERIAL:Compounds expressed by formulas I-III. EXAMPLE:dl-2,3-Dibenzyl-1,4-dimethoxybutane. USE:An antitumor agent. PREPARATION:Hydrocinnamic acid, 3-methoxyhydrocinnamic acid or 3,4- dimethoxyhydrocinnamic acid is reacted with diisopropylamine, n-butyl-lithium and iodine in tetrahydrofuran to provide a compound expressed by formula IV (R1 and R2 are H or OCH3). The resultant compound expressed by formula IV as a raw material is (i) converted into methyl ester, reduced with hydrogen to form an alcohol derivative or further demethylated or (ii) the above-mentioned alcohol derivative is then converted into the methyl ether, acetylated or intramolecularly etherified. Alternatively, (iii) the afore-mentioned raw material is converted into acid anhydride and then reacted with methanol to provide a monoester derivative, which is subsequently reduced with diborane and then heated to form a lactone derivative or further demethylated to afford the aimed compounds expressed by formulas I-III.
The invention belongs to the technical field of cosmetics, and particularly relates to a double-phase whitening essence composition and a use method thereof. The double-phase whitening essence composition consists of water phase essence and oil phase essence. The aqueous phase essence comprises a liquid humectant, a water-soluble whitening component and a water-soluble skin conditioner; the oil phase essence comprises vegetable oil, oil-soluble whitening component and oil-soluble skin conditioner. Because the melanin exists in the water phase and oil phase tissues of the skin, the water phase essence and the oil phase essence can act on the melanin in the water phase and the oil phase tissues respectively, and the whitening is more comprehensive. When in use, a proper amount of one of the cream, the muscle base liquid and the gel is firstly taken and respectively dripped into the palm, one to a plurality of drops of aqueous phase essence and oil phase essence are respectively dripped into the palm, and the mixture is uniformly mixed and then the mixture is smeared on the face. The whitening essence combination can adjust the dosage of the water phase essence and the oil phase essence according to different skin types, seasons and time periods, so that the skin is balanced in water and oil.
The present invention relates to polypeptides and pharmaceutical compositions thereof for treating cancer. Specifically, the amino acid sequence of the polypeptide is shown as SEQ ID NO. 1. The polypeptides of the invention also include mutants of SEQ ID NO. 1. The polypeptide of the present invention can inhibit cancer cell proliferation obviously.
FIELD: chemistry. ^ SUBSTANCE: invention relates to methods for synthesis of new cross-linked salts of hyaluronic acid (HA) which are modified with vitamins - natural polymer from the polysaccharide family. The method involves chemical reaction of a salt of hyaluronic acid, vitamins together with at least one cross-linking agent, simultaneously subjecting the initial reagents to pressure ranging from 5 to 1000 MPa and shear deformation in a mechanochemical reactor at temperature ranging from 20C to 50C. The reactor used is preferably a Bridgman anvil or an auger-type device, e.g. a double-screw extruder. ^ EFFECT: design of a universal environmentally safe method which enables synthesis of a range of new, cross-linked salts of hyaluronic acid which are modified with vitamins, in a single-step production cycle in the absence of a liquid medium, to obtain desired products with quantitative output; the method does not require large energy-, labour- and water inputs, enables use of the most diverse salts of hyaluronic acid as initial reagents. ^ 19 cl, 19 ex
A patient brace system and method of using the same are disclosed for treatment of lower extremity injuries. Described brace systems include a crutch, at least one crutch sensor, a patient brace, at least one controller, and a rehabilitation application. The crutch sensor(s) measure one or more crutch parameters. The controller(s) are operable to receive and process a signal(s) indicative of the crutch parameter(s) and produces patient gait data that, in turn, is communicated to a data hub. In some embodiments, the patient brace may also include at least one brace sensor configured to similarly communicate with the data hub. The rehabilitation application is communication with the data hub and determines a response output based on the information fed to the data hub, the application then communicating the response output to at least one of a caregiver, a user of the patient brace, and/or to the patient brace.
We consider an SEIR epidemic model on a network also allowing random contacts, where recovered individuals could either recover naturally or be diagnosed. Upon diagnosis, manual contact tracing is triggered such that each infected network contact is reported, tested and isolated with some probability and after a random delay. Additionally, digital tracing (based on a tracing app) is triggered if the diagnosed individual is an app-user, and then all of its app-using infectees are immediately notified and isolated. The early phase of the epidemic with manual and/or digital tracing is approximated by different multi-type branching processes, and three respective reproduction numbers are derived. The effectiveness of both contact tracing mechanisms is numerically quantified through the reduction of the reproduction number. This shows that app-using fraction plays an essential role in the overall effectiveness of contact tracing. The relative effectiveness of manual tracing compared to digital tracing increases if: more of the transmission occurs on the network, when the tracing delay is shortened, and when the network degree distribution is heavy-tailed. For realistic values, the combined tracing case can reduce R0 by 20%-30%, so other preventive measures are needed to reduce the reproduction number down to 1.2-1.4 for contact tracing to make it successful in avoiding big outbreaks.
A phamaceutical  composition  is  prepd.  by  (a)  extracting stalk, root, bark or leaves of a elm tree, e.g. Ulmus  davididiana Planch, Ulmus parvifolia Jacq., Ulmus macrocarph Hance, etc., with polar solvent, (b) filtering  the  obtd.  extract  to  obtain  the extracted soln., (c) vacuum-concentrating the obtd. soln to obtain the polar solvent extract and (d) reextracting the  polar  solvent extract with non-polar solvent to obtain the  final  product.  The obtd. phamaceutical composition is useful  for  the  treatment  of tumours.
BACKGROUND: Patients with chronic kidney disease and CAD have been denied revascularization because of fear of precipitating acute renal failure from contrast exposure. Skepticism on whether Ultra-Low contrast percutaneous coronary intervention (PCI) or Zero contrast PCI (ULC/ZC PCI) can be safely performed has limited its adoption.
METHODS: This observational registry enrolled 200 consecutive patients referred for elective PCI at a single center from June 2021 to December 2022. The study investigated whether the clinical outcomes of PCI performed with UL/ZC-PCI (n-48) were comparable to outcomes following standard PCI (n-152).
RESULTS: Both groups were well matched in baseline and procedural characteristics. The groups had a highly statistical difference in the use of CV. Mean CV was 19.17 ± 7.29 cc in the ULC/ZC-group and 147.14 ± 73.55 cc in the control arm. The principal findings of the study were that the incidence of ontrast-induced acute kidney injury (AKI) was eightfold lower in patients receiving UL/ZC compared to the control group that received standard PCI. The incidence of all-cause mortality, myocardial infarction and major bleeding were similar in both groups. At 6 months, the decrement in renal function was lower in the group that received lower volumes of contrast.
CONCLUSIONS: This single center observational registry demonstrated that UL-C/ZC-PCI is safe and effective in a broad spectrum of complex lesions. The skillsets needed to perform this are teachable, widely applicable and do not require a large upgrade of capital equipment. AKI rates and decrement in renal function at 6 months were both significantly lower in the UL-ZC group.
No intervention apart from application of clearsight monitor. Prior to induction of anaesthesia the control group will have a Clearsight cardiac monitor probe placed on a suitable finger and baseline haemodynamic measurements will be taken. All fluid management and administration of vasopressor therapy will be at the discretion of the anaesthetist as per the current practice at the host institution. Data on stroke volume, heart rate, blood pressure, cardiac output, oxygen saturations, will be recorded at baseline and then every 5 minutes.
After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40mg Valsartan twice daily qd for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
The present invention relates to antibody preparations comprising antibodies or antigen binding fragments thereof which specifically binds to IGF-1R comprising CDR H3 of SEQ. ID. NO: 1 or a variant thereof which contains 1 or 2 amino acid substitutions in the CDRH3. In one embodiment the invention provides an antibody or antigen binding fragment thereof which specifically binds IGF-1R, specifically hIGF-1R and neutralises the activity of hIGF-1R, which comprises a heavy chain variable domain comprising CDR H3 of SEQ. ID. NO: 1 or variants thereof in which one or two amino acid residues within CDR H3 differ from the amino acid residues in the corresponding position in SEQ. ID. NO: 1. Compositions comprising such antibody preparations and methods of producing and uses thereof are also included within the scope of the present invention.
The present invention concerns fibroblast growth factor receptor 3 (FGFR3) as a novel marker for mesenchymal skeletal progenitor cells. By utilizing this novel marker it was possible both to identify and locate mesenchymal skeletal progenitor cells in a tissue, as well as to obtain a substantially pure culture of such cells. The pure culture of the mesenchymal skeletal progenitor cells may be used, optionally after various manipulations ex vivo, as an active ingredient in pharmaceutical compositions or implants for the purpose of bone and/or cartilage repair. FGFR3 may also be used as a marker for the identification and the localization of cartilage- and bone-derived tumors. Agents capable of binding to FGFR3 may also be used for targeting cytotoxic agents to cartillage- and bone-derived tumors.The present invention concerns fibroblast growth factor receptor 3 (FGFR3) as a novel marker for mesenchymal skeletal progenitor cells. By utilizing this novel marker it was possible both to identify and locate mesenchymal skeletal progenitor cells in a tissue, as well as to obtain a substantially pure culture of such cells. The pure culture of the mesenchymal skeletal progenitor cells may be used, optionally after various manipulations ex vivo, as an active ingredient in pharmaceutical compositions or implants for the purpose of bone and/or cartilage repair. FGFR3 may also be used as a marker for the identification and the localization of cartilage- and bone-derived tumors. Agents capable of binding to FGFR3 may also be used for targeting cytotoxic agents to cartillage- and bone-derived tumors.
BACKGROUND: After a 40% reduction in maternal mortality ratio (MMR) during 2001-2010 in Bangladesh, the MMR level stagnated between 2010 and 2016 despite a steady increase in maternal health services use and improvements in overall socioeconomic status. We revisited the factors that contributed to MMR decline during 2001-2010 and examined the changes in these factors between 2010 and 2016 to explain the MMR stagnation in Bangladesh.
METHODS: We used data from the 2001, 2010, and 2016 Bangladesh Maternal Mortality Surveys, which sampled 566 115 households in total, to estimate the changes in the risk of dying of maternal causes associated with a pregnancy or birth between 2001-2010 and 2010-2016. We carried out Poisson regression analyses with random effects at the sub-district level to explore the relationship between the change in risk of maternal death from 2001 to 2016 and a range of demographic, socioeconomic, and health care factors.
RESULTS: Between 2001 and 2016, the proportion of high-risk pregnancies decreased, except for teenage pregnancies. Meanwhile, there were notable improvements in socioeconomic status, access to health services, and the utilisation of maternal health services. A comparison of factors affecting the risk of maternal death between 2001-2010 and 2010-2016 indicated that first pregnancies continued to offer significant protection against maternal deaths. However, subsequent pregnancies among girls under 20 years became a significant risk factor during 2010-2016, increasing the risk of maternal deaths by nearly 3-fold. Among the key maternal health services, only skilled birth attendants (SBA) were identified as a key contributor to MMR reduction during 2001-2010. However, SBA is no longer significantly associated with reducing mortality risk during 2010-2016.
CONCLUSIONS: Despite continued improvements in the overall socioeconomic status and access to maternal health services in Bangladesh, the stagnation of MMR decline between 2010 and 2016 is associated with multiple teenage pregnancies and the lack of capacity in health facilities to provide quality delivery services, as SBA has been primarily driven by facility delivery. The findings provide a strong rationale for targeting at-risk mothers and strengthening reproductive health services, including family planning, to further reduce maternal mortality in Bangladesh.
Subjects will visit the site 5 times. The first visit, is a 2 hour screening visit for eligibility in which volunteers after signing informed consent will have a medical history, physical examination, ECG, hematological and biochemical blood tests, Mini Mental State Examination (MMSE), Geriatric Depression scale (GDS-30) and body sway test.

Eligible subjects will be randomly allocated to receive three doses Namisol® (3 mg or 5 mg or 6,5 mg) and placebo in double-blind crossover design (visit 1 to 4). The wash-out period between visits will be at least 2 weeks to a maximum of 4 weeks. Each visit will be preceded by baseline assessment measures. The safety and tolerability profiles of Namisol® will be evaluated on each intervention visit by using a standardized THC adverse effects checklist and self-reporting, vital signs, 12-lead ECG, body sway, Visual Analogue Scales (subtest feeling high), and Test for Attentional Performance (TAP, subtest alertness) and a follow up phone call the following day. Four blood samples will be collected on each visit to determine the relationship between the pharmacodynamic effects (VAS-feeling high, TAP-alertness and body sway) and the plasma concentrations of THC and its active metabolites 11-OH-THC and THC-COOH. In addition, a blood sample will be only collected on the first intervention day for genotyping of cytochrome P450 enzymes CYP2C9 CYP2C19 and CYP3A4.
The invention relates to preparation of GPI-induced insulin targeted exosomes and application thereof in delivery of recombinant biological drugs. The method comprises the construction of pMCP-GPI-Insulin and pFlag-CMV-2-Kex2-EK-Rt-sirt2 plasmids. pMCP-GPI carrying GPI genes and pGEM-T-Insulin carrying Insulin targeting molecules are recombined to construct pMCP-GPI-Insulin, after the pMCP-GPI-Insulin is transfected to MSC cells, insulin is stably expressed and carried by exosomes, and the exosomes are enriched on the surfaces of target cells. The pFlag-CMV-2-Rt-sirt2 carrying the rhodotorula glutinis sirt2 gene and the pMD18-T-Kex2-EK carrying the secretion signal peptide gene are recombined to construct pFlag-CMV-2-Kex2-EK-Rt-sirt2, and the pFlag-CMV-2-Kex2-EK-Rt-sirt2 gene is transfected into the MSC cells to enable the MSC cells to secrete insulin receptor target wrapping sirt2 protein to exosomes. Experiments of a mouse liver cell model with mitochondrial dysfunction prove that after the action of exosome, the intracellular ROS level is reduced, the activity of antioxidant enzyme is increased, the mitochondrial membrane potential is reduced, the mtDNA content is increased, the expression of mitochondrial key factors is increased, and the mitochondrial structure is improved. The invention provides a new strategy for treating diseases related to mitochondrial dysfunction.
Ketorolac tromethamine cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.

The pharmacological activity of ketorolac tromethamine in reducing inflammation may diminish the utility of this diagnostic sign in detecting complications of presumed noninfectious, painful conditions.

Hepatic Effect

Ketorolac tromethamine should be used with caution in patients with impaired hepatic function or a history of liver disease. Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including ketorolac tromethamine. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported.

A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with ketorolac tromethamine. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), ketorolac tromethamine should be discontinued.

Hematologic Effect

Anemia is sometimes seen in patients receiving NSAIDs, including ketorolac tromethamine. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including ketorolac tromethamine, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia. NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving ketorolac tromethamine who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored.
Biweekly sessions will be held for 6 months (a total of 12 sessions per family) via videoconference with the family at home. Each session will last approximately 1 hour to 1 hour and 30 minutes and will work with the primary caregiver. The intervention protocol mixes coaching strategies based on observation and video-feedback. This arm will provide with measurements at waves 0,1, and 2 over a time period of approximately 12 months.